Pulse Biosciences Files 510(k) Submission with U.S. FDA for its CellFX® nsPFA™ Cardiac Clamp

Pulse Biosciences, Inc. , a company primarily focused on leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation technology for the treatment of atrial fibrillation, today...

Related Keywords

United States ,Bioscience Cell ,Kevin Danahy ,Pulse Biosciences Inc ,Exchange Commission ,Drug Administration ,Nasdaq ,Company Cell ,Pulse Biosciences ,Pulsed Field Ablation ,Chief Science Officer ,Cardiac Surgery ,Gan Dunnington ,Chief Medical Officer ,Chief Executive Officer ,Nano Pulse Stimulation ,Pulse Bioscience ,Markets ,